# Tumor Imaging Core

> **NIH NIH P01** · PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED · 2020 · $293,707

## Abstract

PROJECT SUMMARY_CORE C 
Core C Preclinical Tumor Imaging will provide services and expertise to all PPG investigators in designing and 
executing imaging experiments required to meet the objectives of each project. Core personnel will: 1) assist 
with design and execute imaging experiments; 2) store, process, and distribute as needed, all tissues required 
for downstream analysis, or use in other projects; 3) assist or directly perform all animal imaging experiments 
needed; 4) assist or directly perform all animal and imaging data analyses and interpretation; and 5) facilitate 
archiving and retrieval of data. Investigators will be advised of the full potential of Core C capabilities to ensure 
that experimental designs fully utilize available services. Preclinical tumor imaging capabilities available include 
Single Photon Emission Computed Tomography combined with X-ray CT (SPECT-CT) for whole-body imaging, 
intravital microscopy (IVM) and static microscopy imaging. Each of our imaging modalities described is well- 
suited to focus on a specific aspect of antibody targeting and processing. The multiple imaging approaches 
provided by Core C will complement and confirm one another, and will provide a more complete analysis of 
targeting, delivery and processing in vivo at multiple levels. Data acquired will assist in: 1) validating AnnA1 
expression by examining tissue sections using histochemical and fluorescence based assays; 2) defining and 
quantifying tumor targeting by hAnnA1 antibodies over time using dynamic whole-body imaging; and 3) 
evaluating and quantifying EC processing of hAnnA1 targeted immunocomplexes and conjugates via dynamic 
IVM in novel human tumor models. Core C services will help answer key questions on the distribution of AnnA1 
in human tissues, on how tumors process specific probes in vivo, and how caveolae function in the tumor 
vascular endothelium. Data from preclinical image analysis will be used to assess the effectiveness of drugs and 
imaging agents for development in Projects 1 and 2, and eventual clinical utility in Project 3.

## Key facts

- **NIH application ID:** 9974492
- **Project number:** 5P01CA221775-02
- **Recipient organization:** PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED
- **Principal Investigator:** Adrian Chrastina
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $293,707
- **Award type:** 5
- **Project period:** 2019-07-08 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9974492

## Citation

> US National Institutes of Health, RePORTER application 9974492, Tumor Imaging Core (5P01CA221775-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9974492. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*